Stephen Ruhmel

Stephen Ruhmel is an Associate Director at The Janssen Pharmaceutical Companies of Johnson & Johnson currently working in Janssen Clinical Innovation (JCI), a team dedicated to delivering clinical trial efficiencies and innovation for patients, investigators and the industry at large. He has worked across teams at Janssen and J&J for over 12 years in Global Public Health, Global Development, Digital Health, R&D, and IT.
Stephen is currently working with internal and external partners to develop speech-based capabilities in clinical trials, including conversational AI and speech biomarkers, with the objective of creating novel clinical outcome measures in the areas of Neuroscience and Alzheimer’s. Prior to his current role, Stephen developed and launched a SXSW-award-winning crowdfunding platform, CaringCrowd, and has contributed to research projects throughout Africa focused on mental illness, infectious diseases, and nursing/midwifery professions.